Paper
0
Randomized Phase II Trial of Immunotherapy-Based Total Neoadjuvant Therapy for Proficient Mismatch Repair or Microsatellite Stable Locally Advanced Rectal Cancer (TORCH)
Authors
Fan Xia,Yaqi Wang
Hui Wang,Lijun Shen,Zuo‐Lin Xiang,Yutian Zhao,Huo-Jun Zhang,Juefeng Wan,Hui Zhang,Yan Wang,Ruiyan Wu,Jingwen Wang,Yang Wang,Mengqian Zhou,Shujuan Zhou,Yajie Chen,Zhiyuan Zhang,Xian Wu,Yan Xuan,Renjie Wang,Yiqun Sun,Tong Tong,Xun Zhang,Lei Wang,Dan Huang,Weiqi Sheng,Hao Yan,Yang Xu,Yuxin Shen,Yu Xu,Ruping Zhao,Miao Mo,Guoxiang Cai,Sanjun Cai,Ye Xu
+33 authors
,Zhen ZhangJournal
Published
Jul 1, 2024
Show more
Save
Tip0
TipSave
Abstract
To assess whether the integration of PD-1 inhibitor with total neoadjuvant therapy (iTNT) can lead to an improvement in complete responses (CRs) and favors a watch-and-wait (WW) strategy in patients with proficient mismatch repair or microsatellite stable (pMMR/MSS) locally advanced rectal cancer (LARC).
Paper PDF
This paper's license is marked as closed access or non-commercial and cannot be viewed on ResearchHub. Visit the paper's external site.